Listar por autor "Panteliadou, M."
Mostrando ítems 1-3 de 3
-
Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC)
Panteliadou, M.; Touloupidis, S.; Giatromanolaki, A.; Pistevou, K.; Kyrgias, G.; Tsoutsou, P.; Kalaitzis, C.; Koukourakis, M. I. (2011)Cisplatin-based radio-chemotherapy is an effective alternative to cystectomy. The position of cisplatin has been challenged by novel drugs, while altered radiotherapy fractionation is also tested against conventional ... -
Dose Escalation of Amifostine for Radioprotection During Pelvic Accelerated Radiotherapy
Koukourakis, M. I.; Kyrgias, G.; Panteliadou, M.; Papadopoulou, A.; Tsiarkatsi, M.; Papachristou, E.; Bebeli, M. (2013)Objectives: Experimental data suggest a dose-dependent efficacy of amifostine so that the low overall doses used in clinical trials may have masked the full potential of the drug. In this study, we report our experience ... -
Treatment of Low-risk Prostate Cancer with Radical Hypofractionated Accelerated Radiotherapy with Cytoprotection (HypoARC): An Interim Analysis of Toxicity and Efficacy
Koukourakis, M. I.; Kyrgias, G.; Papadopoulou, A.; Panteliadou, M.; Giatromanolaki, A.; Sivridis, E.; Mavropoulou, S.; Kalogeris, K.; Nassos, P.; Milioudis, N.; Touloupidis, S. (2011)Aim: Radiobiological analysis of clinical data suggests that prostate cancer has a low alpha/beta ratio, implying that large radiotherapy fractions may better control the disease. Acceleration of radiotherapy may be also ...